{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:32:55Z","timestamp":1787031175632,"version":"build-2736575974"},"reference-count":19,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n                  <jats:p>\n                    AT-752 is a novel guanosine nucleotide prodrug inhibitor with pan-serotype antiviral activity against dengue virus. In this phase 2, randomized, double-blind, placebo-controlled study, we evaluated the activity, safety, and pharmacokinetics of oral AT-752 (750 mg thrice daily for 5 days) compared with a placebo in 21 adults with confirmed dengue infection. The primary endpoint was the change from baseline in viral load via reverse transcription quantitative polymerase chain reaction testing, with assessments performed daily on Days 1\u20138, 14, and 28. The primary endpoint was nonevaluable because many patients presented late during the course of disease, with low baseline viremia levels precluding accurate quantification at subsequent timepoints. In the as-treated population (patients with assessment at baseline and at each post-baseline timepoint), the numerical mean reduction (versus baseline) in viral load on Day 4 was greater in the AT-752 group than the placebo group (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.0022). The median time to a sustained resolution of fever (the major clinical sign of dengue) was 4 days in the AT-752 group compared with &gt;5 days in the placebo group; the reduction in oral temperature at the Day 4 timepoint was greater in the AT-752 group (treatment difference: 0.84\u00b0C;\n                    <jats:italic>P<\/jats:italic>\n                    = 0.0322). There was a trend toward faster platelet recovery in the AT-752 group compared with the placebo group, and proportionally fewer patients in the AT-752 group underwent hospitalization for disease progression (one patient in each group). AT-752 exhibited favorable safety and tolerability; the majority of adverse events were mild or moderate, and Grade 3 or 4 adverse events occurred at similar rates in both groups. These data support the further evaluation of AT-752 in treating dengue in future clinical trials.\n                  <\/jats:p>","DOI":"10.4269\/ajtmh.24-0696","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T19:30:10Z","timestamp":1752175810000},"page":"498-507","source":"Crossref","is-referenced-by-count":7,"title":["Safety, Pharmacokinetics, and Activity of AT-752, a Novel Nucleotide Prodrug with Pan-Serotype Activity against Dengue Virus: A Phase 2, Randomized, Double-Blind Study"],"prefix":"10.4269","volume":"113","author":[{"given":"Arantxa","family":"Horga","sequence":"first","affiliation":[{"name":"Atea Pharmaceuticals, Inc., Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro M.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Belo Horizonte, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnav","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Down Town Hospital, Guwahati, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannan","family":"Lynch","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc., Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Chin","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc., Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ishak","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc., Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc., Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Pietropaolo","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc., Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Belanger","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc., Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lei","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc., Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc., Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Hammond","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Inc., Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"821","article-title":"Travel-associated dengue cases \u2013 United States, 2010\u20132021","volume":"72","author":"Wong","year":"2023"},{"key":"b2","series-title":"Emerg Reemerg Viral Pathogens","first-page":"281","article-title":"Dengue virus","volume":"2020","author":"Murugesan","year":"2020"},{"key":"b3","article-title":"Disease Outbreak News. Dengue \u2013 Global Situation","year":"2023"},{"key":"b4","article-title":"Dengue and Severe Dengue","year":"2024"},{"key":"b5","series-title":"Curr Treat Options Infect Dis","first-page":"27","article-title":"Dengue: Update on clinically relevant therapeutic strategies and vaccines","volume":"15","author":"Palanichamy Kala","year":"2023"},{"key":"b6","article-title":"Dengvaxia"},{"key":"b7","article-title":"Dengvaxia"},{"key":"b8","series-title":"J Gen Virol","first-page":"1831","article-title":"Challenges on the development of a dengue vaccine: A comprehensive review of the state of the art","volume":"104","author":"Pintado Silva","year":"2023"},{"key":"b9","series-title":"Front Cell Infect Microbiol","first-page":"572681","article-title":"Antibody-dependent enhancement: A challenge for developing a safe dengue vaccine","volume":"10","author":"Shukla","year":"2020"},{"key":"b10","article-title":"Takeda\u2019s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years","year":"2023"},{"key":"b11","series-title":"N Engl J Med","first-page":"397","article-title":"Live, attenuated, tetravalent Butantan-dengue vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024"},{"key":"b12","series-title":"Lancet Infect Dis","first-page":"706","article-title":"Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"14","author":"Low","year":"2014"},{"key":"b13","series-title":"J Infect Dis","first-page":"1442","article-title":"A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients","volume":"207","author":"Nguyen","year":"2013"},{"key":"b14","series-title":"PLoS Negl Trop Dis","first-page":"e785","article-title":"A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults","volume":"4","author":"Tricou","year":"2010"},{"key":"b15","series-title":"Clin Infect Dis","first-page":"468","article-title":"Lovastatin for the treatment of adult patients with dengue: A randomized, double-blind, placebo-controlled trial","volume":"62","author":"Whitehorn","year":"2016"},{"key":"b16","series-title":"Elife","first-page":"RP92606","article-title":"Dengue viremia kinetics and effects on platelet count and clinical outcomes: An analysis of 2340 patients from Vietnam","volume":"13","author":"Vuong","year":"2024"},{"key":"b17","series-title":"Parasit Vectors","first-page":"590","article-title":"Evaluation of host and viral factors associated with severe dengue based on the 2009 WHO classification","volume":"7","author":"Pozo-Aguilar","year":"2014"},{"key":"b18","series-title":"Antimicrob Agents Chemother","first-page":"e0098821","article-title":"Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in\u00a0vitro and in\u00a0vivo activity against dengue and other flaviviruses","volume":"65","author":"Good","year":"2021"},{"key":"b19","series-title":"Antimicrob Agents Chemother","first-page":"e0161523","article-title":"First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus","volume":"68","author":"Zhou","year":"2024"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/113\/3\/article-p498.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/113\/3\/article-p498.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/113\/3\/article-p498.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T13:13:29Z","timestamp":1756905209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/113\/3\/article-p498.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":19,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.24-0696","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}